ALKEM · Healthcare
Alkem Laboratories Ltd. reported revenue of ₹3,603 cr for January to March 2026, +14.6% on the year and −3.6% on the quarter. Over the last four quarters revenue comes to ₹14,712 cr, +13.5% on the four before.
Operating profit (EBITDA) was ₹517 cr, a margin of 14.3%, +191 bps on the year and −781 bps on the quarter. Over the last 8 quarters the margin has ranged from 12.4% to 23.0%, averaging 19.8%. Operating costs grew +12.1% against revenue growth of +14.6%, so more of each rupee of sales reached operating profit.
Net profit was ₹251 cr, −22.0% on the year and −61.6% on the quarter, with earnings per share of ₹19.78. Profit before other income, one-offs and tax grew faster, at +43.2%; other income, one-offs or tax held the headline back. The tax rate was 40% against an average of 14% over the previous 8 quarters, which weighed on profit this quarter. Profit over the last four quarters totals ₹2,351 cr, +6.1% on the four before.
On earnings per share of ₹192.52 over the last four quarters, the stock at ₹5,302.00 trades at 27.5 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Core profit grew faster than reported profit: one-offs held the headline down.
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,440 cr | ₹3,324 cr | ₹2,936 cr | ₹3,032 cr | ₹3,415 cr | ₹3,374 cr | ₹3,144 cr | ₹3,371 cr | ₹4,001 cr | ₹3,737 cr | ₹3,603 cr | ₹3,740 cr |
| YoY | — | — | — | +2% | −1% | +2% | +7% | +11% | +17% | +11% | +15% | +11% |
| EBITDA margin | 21.7% | 21.3% | 13.7% | 20.1% | 22.0% | 22.5% | 12.4% | 21.9% | 23.0% | 22.2% | 14.3% | 20.5% |
| Other income, % of PBT | 1% | 6% | 21% | 19% | 17% | 13% | 37% | 19% | 12% | 12% | 15% | 20% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net profit | ₹615 cr | ₹604 cr | ₹304 cr | ₹550 cr | ₹702 cr | ₹641 cr | ₹322 cr | ₹668 cr | ₹779 cr | ₹653 cr | ₹251 cr | ₹521 cr |
| YoY | — | — | — | +91% | +14% | +6% | +6% | +21% | +11% | +2% | −22% | −22% |
| Core profit YoY | — | — | — | +74% | +1% | +4% | −14% | +25% | +23% | +8% | +43% | −0% |
| EPS | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.58 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.78 | ₹43.49 |
| Flags | · | · | · | 1 | ✓ | ✓ | 2 | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Alkem Laboratories Ltd. reported revenue of ₹3,603 cr (+14.6% on the year) and net profit of ₹251 cr (−22.0% on the year) for January to March 2026.
Profit before other income, exceptional items and tax moved +43.2% on the year, against −22.0% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.